Inter-chain disulfide bond improved protein trans-splicing increases plasma coagulation activity in C57BL/6 mice following portal vein FVIII gene delivery by dual vectors

Protein trans-splicing based dual-vector factor VIII (FVIII) gene delivery is adversely affected by less efficiency of protein splicing. We sought to increase the amount of spliced FVIII protein and plasma coagulation activity in dual-vector FVIII transgene in mice by means of strengthening the interaction of inteins, protein splicing elements, thereby facilitating protein trans-splicing. Dual-vector delivery of the FVIII gene in cultured cells showed that replacement of Met226 in the heavy chain and Asp1828 in the light chain with Cys residues could facilitate inter-chain disulfide linking and improve protein trans-splicing, increasing the levels of spliced FVIII protein. In this study, C57BL/6 mice were coadministered dual vectors of intein-fused human FVIII heavy chain and light chain with Cys mutations via portal vein injection into the liver. Forty-eight hours post-injection, plasma was collected and analyzed for FVIII antigen concentration and coagulation activity. These mice showed increased circulating FVIII heavy chain polypeptide (442±151 ng mL−1 vs. 305±103 ng mL−1) and coagulation activity (1.46±0.37 IU m−1 vs. 0.85±0.23 IU mL−1) compared with control mice co-administered dual vectors expressing the heavy and light chains of wild-type FVIII. Moreover, coagulation activity was similar to that of mice receiving a single vector expressing FVIII (1.79±0.59 IU mL−1). These findings indicate that improving protein trans-splicing by inter-chain disulfide bonding is a promising approach for increasing the efficacy of dual-vector based FVIII gene transfer.

[1]  V. Haurigot,et al.  Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. , 2010, Blood.

[2]  T. Muir,et al.  Biological Applications of Protein Splicing , 2010, Cell.

[3]  R. Kaufman,et al.  Mutagenesis of a Potential Immunoglobulin-binding Protein-binding Site Enhances Secretion of Coagulation Factor VIII* , 1997, The Journal of Biological Chemistry.

[4]  Randal J. Kaufman,et al.  Endoplasmic Reticulum Stress Activates Cleavage of CREBH to Induce a Systemic Inflammatory Response , 2006, Cell.

[5]  B. Byrne,et al.  Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice. , 2003, Human gene therapy.

[6]  R. Kaufman.  Genetic engineering of factor VIII , 1989, Nature.

[7]  R. Herzog,et al.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. , 2009, Blood.

[8]  A. Dorner,et al.  Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. , 1988, The Journal of biological chemistry.

[9]  Jing Miao,et al.  Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors , 2012, Science China Life Sciences.

[10]  H. Wu,et al.  Protein trans-splicing and functional mini-inteins of a cyanobacterial dnaB intein. , 1998, Biochimica et biophysica acta.

[11]  H. Kazazian,et al.  Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  FuXiang Zhu,et al.  Protein trans-splicing based dual-vector delivery of the coagulation factor VIII gene , 2010, Science China Life Sciences.

[13]  J. Griffin,et al.  Intrinsic stability and functional properties of disulfide bond‐stabilized coagulation factor VIIIa variants , 2006, Journal of thrombosis and haemostasis : JTH.

[14]  R. Sarkar,et al.  The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Jing Miao,et al.  The effect of a secretion-enhanced heavy chain on improving intein-based dual-vector co-delivery of a full-length factor VIII gene , 2011 .

[16]  H. Kazazian,et al.  Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. , 2003, Blood.

[17]  R. Mitchell,et al.  Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Pipe.  Coagulation factors with improved properties for hemophilia gene therapy. , 2004, Seminars in thrombosis and hemostasis.

[19]  H. Kazazian,et al.  Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. , 2006, Human gene therapy.

[20]  Miao Jing,et al.  Cys Mutation of Met662 and Asp1828 Strengthens Splicing of Co-expressed B-domain-deleted FV III Heavy and Light Chains by Intein , 2012 .